These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
158 related items for PubMed ID: 35170858
1. Combination of MRI prostate and 18F-DCFPyl PSMA PET/CT detects all clinically significant prostate cancers in treatment-naive patients: An international multicentre retrospective study. Parathithasan N, Perry E, Taubman K, Hegarty J, Talwar A, Wong LM, Sutherland T. J Med Imaging Radiat Oncol; 2022 Oct; 66(7):927-935. PubMed ID: 35170858 [Abstract] [Full Text] [Related]
2. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L. Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891 [Abstract] [Full Text] [Related]
3. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669 [Abstract] [Full Text] [Related]
4. Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, Meijer D, de Bie K, Yaqub M, Windhorst BAD, Hendrikse HNH, Vis AN, Oprea-Lager DE. Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727 [Abstract] [Full Text] [Related]
6. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L. BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [Abstract] [Full Text] [Related]
14. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M. Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337 [Abstract] [Full Text] [Related]
15. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, Gondoputro W, Katelaris A, Haynes AM, Delprado W, O'Neill G, Yuen C, Vis AN, van Leeuwen PJ, Ho B, Liu V, Lee J, Donswijk ML, Oprea-Lager D, Scheltema MJ, Emmett L, Stricker PD. BJU Int; 2024 Apr; 133 Suppl 4():14-22. PubMed ID: 37858931 [Abstract] [Full Text] [Related]
16. Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [18F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients. Fu Y, Zhao M, Chen J, Wen Q, Chen B. Sci Rep; 2024 Jul 05; 14(1):15525. PubMed ID: 38969741 [Abstract] [Full Text] [Related]
17. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. Tran V, Hong A, Sutherland T, Taubman K, Lee SF, Lenaghan D, Sethi K, Corcoran NM, Lawrentschuk N, Woo H, Tarlinton L, Bolton D, Spelman T, Thomas L, Booth R, Hegarty J, Perry E, Wong LM. BMJ Open; 2022 Sep 19; 12(9):e061815. PubMed ID: 36123093 [Abstract] [Full Text] [Related]
18. Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer. Liu Y, Dong Y, Liu J, Zhang X, Lin M, Xu B. Prostate; 2021 Dec 19; 81(16):1329-1336. PubMed ID: 34516670 [Abstract] [Full Text] [Related]
19. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study. Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W. Theranostics; 2021 Dec 19; 11(17):8396-8411. PubMed ID: 34373749 [Abstract] [Full Text] [Related]